Clinical Trial: NCT03004833
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | University of Cologne |
| Information Provided By: | University of Cologne |
| Last Update Posted: | 2025-04-03 |
Study Overview
Brief Summary
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD).
The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.
Official Title
Conditions
Intervention / Treatment
- Drug: Nivolumab
- Drug: Adriamycin
- Drug: Vinblastine
- Drug: Dacarbazine
Other Study ID Numbers
- Uni-Koeln-2854
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | University of Cologne |
| Information Provided By: | University of Cologne |
| Last Update Posted: | 2025-04-03 |
Study Overview
Brief Summary
The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD).
The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.
Official Title
Conditions
Intervention / Treatment
- Drug: Nivolumab
- Drug: Adriamycin
- Drug: Vinblastine
- Drug: Dacarbazine
Other Study ID Numbers
- Uni-Koeln-2854